Log in to search using one of your social media accounts:

 

Novo Nordisk Settles U.S. Probe Over Diabetes Drug for Nearly $58.7 Mln Novo Nordisk Settles U.S. Probe Over Diabetes Drug for Nearly $58.7 Mln
Novo Nordisk will pay nearly $58.7 million to resolve claims the drugmaker's sales staff downplayed the importance of U.S. Food and Drug Administration-mandated warnings about the cancer risks of its diabetes medication Victoza (liraglutide).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 6, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Nordisk settles DOJ ’ s Victoza marketing suit for $59m
Novo Nordisk (NYSE:NVO)  said yesterday afternoon that it inked a $58.7 million deal with the U.S. Dept. of Justice to settle an investigation into the company’s marketing practices for Victoza – its Type II diabetes drug. The agreement settles eight different lawsuits alleging that the drugmaker misled doctors by dressing salespeople as medical educators, paying physicians to prescribe its liraglutide drug and downplaying the medicine’s side effects. Get the full story at our sister site, Drug Delivery Business News. The post Nordisk settles DOJ’s Victoza marketing suit for $59m appeared ...
Source: Mass Device - September 6, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Legal News Pharmaceuticals Wall Street Beat Novo Nordisk Source Type: news

Novo Nordisk settles U.S. probe over diabetes drug for nearly $58.7 million
(Reuters) - Novo Nordisk will pay nearly $58.7 million to resolve claims the drugmaker's sales staff downplayed the importance of a warning about cancer risks on the label of its diabetes medication Victoza, the U.S. Justice Department said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - September 5, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Liraglutide Reduces Renal Risks in Type 2 Diabetes (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM Liraglutide — a glucagon-like peptide 1 (GLP-1) agonist — lowers risks for kidney disease in patients with type 2 diabetes, according to a secondary analysis from an … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 30, 2017 Category: Primary Care Source Type: news

Victoza ® reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events
A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk, irrespective of their history of having a heart attack and/or stroke or not having any of these events, when compared to placebo.(1) This post-hoc analysis was presented today at the European Society of Cardiology (ESC) Annual Congress in Barcelona, Spain. (Source: World Pharma News)
Source: World Pharma News - August 28, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news

Liraglutide Indicated to Reduce Risk for Cardiovascular Events (FREE)
By Kelly Young Edited by Susan Sadoughi, MD, and Andr é Sofair, MD, MPH The type 2 diabetes drug liraglutide (Victoza) has received a new indication, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 28, 2017 Category: Primary Care Source Type: news

D.C. Week: Trump Pressures Congress on ACA Repeal
(MedPage Today) -- Also, FDA okays new indication for diabetes drug liraglutide (Victoza) (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 26, 2017 Category: American Health Source Type: news

Victoza (liraglutide) is Approved to Reduce the Risk of Three Major Adverse Cardiovascular Events in Type 2 Diabetes Patients
PLAINSBORO, N.J., Aug. 25, 2017 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved a new indication for Victoza (liraglutide) to reduce the risk of major adverse cardiovascular (CV) events, heart attack, stroke and CV death, in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 25, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Grants Liraglutide Cardiovascular Events Indication FDA Grants Liraglutide Cardiovascular Events Indication
Liraglutide becomes the second glucose-lowering drug, after empagliflozin, to receive an additional indication for cardiovascular risk reduction.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

Another Diabetes Drug Scores Heart Indication
(MedPage Today) -- Liraglutide follows empagliflozin into cardiovascular approval (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 25, 2017 Category: Urology & Nephrology Source Type: news

FDA clears Nordisk ’s Victoza as only Type II diabetes drug to cut cardio risks
The FDA approved a new indication for Novo Nordisk‘s (NYSE:NVO) Victoza liraglutide injection, clearing it as the only Type II diabetes medication indicated to reduce the risk of cardiovascular diseases, like heart attack and stroke. The regulatory watchdog’s decision is based on results from Nordisk’s 9,300-patient Leader trial, which showed that Victoza significantly reduced the risk of cardiovascular death, non-fatal heart attack and non-fatal stroke. Get the full story at our sister site, Drug Delivery Business News. The post FDA clears Nordisk’s Victoza as only Type II diabetes drug to cut...
Source: Mass Device - August 25, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Novo Nordisk Source Type: news

In Europe, Changes to Liraglutide Label to Reflect LEADER In Europe, Changes to Liraglutide Label to Reflect LEADER
Product labeling of Saxenda has been changed and a new indication endorsed for Victoza, both reflecting liraglutide's cardiovascular event reduction potential.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 28, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

FDA committee supports Nordisk ’ s cardiovascular risk claim for Victoza label
Novo Nordisk (NYSE:NVO) shares ticked up 1% earlier this week after an advisory committee for the FDA voted to recommend that the company’s cardiovascular risk reduction claim be added to its Victoza (liraglutide) label. The discussions among committee members involved data from the 9,300-patient Leader trial, which involved people with Type II diabetes at high risk of major cardiovascular events. Get the full story at our sister site, Drug Delivery Business News. The post FDA committee supports Nordisk’s cardiovascular risk claim for Victoza label appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - June 22, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Clinical Trials Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Wall Street Beat Novo Nordisk Source Type: news

FDA Panel Backs Liraglutide to Reduce CV Risk Factors FDA Panel Backs Liraglutide to Reduce CV Risk Factors
An FDA panel recommended liraglutide for the additional indication of reducing the risk for major adverse cardiovascular events in adults with type 2 diabetes mellitus and high cardiovascular risk.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 21, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

FDA Panel Says Yes to CV Indication for Liraglutide
(MedPage Today) -- But questioned lack of benefit in U.S. subgroup in LEADER trial (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 20, 2017 Category: American Health Source Type: news

Clear Sailing Likely for Victoza CV Indication
(MedPage Today) -- No major issues put forth for Tuesday FDA advisory committee (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - June 19, 2017 Category: Urology & Nephrology Source Type: news

Clear Sailing Likely for Liraglutide CV Indication
(MedPage Today) -- No major issues put forth for Tuesday FDA advisory committee (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 19, 2017 Category: American Health Source Type: news

Novo Nordisk Looks to Expand Latin American Obesity Business Novo Nordisk Looks to Expand Latin American Obesity Business
Danish drugmaker Novo Nordisk is looking to expand its obesity business in Latin America on the back of"phenomenal" performance by its new anti-obesity injection Saxenda (liraglutide), a senior company official said on Monday.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 23, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Novo Nordisk launches Xultophy diabetes therapy in U.S.
Novo Nordisk (NYSE:NVO) said today that it launched its Type II diabetes combination therapy, Xultophy, in pharmacies across the U.S. The injection is a combination of insulin degludec and liraglutide that is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type II diabetes. In clinical trials, Xultophy reduced A1C and lowered blood sugar for 24 hours, according to Nordisk. Get the full story at our sister site, Drug Delivery Business News. The post Novo Nordisk launches Xultophy diabetes therapy in U.S. appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - May 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Pharmaceuticals Wall Street Beat Novo Nordisk Source Type: news

Liraglutide cost effective for T2DM in Spain
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2017 Category: Drugs & Pharmacology Source Type: news

Nordisk wins label update for weight loss drug-device combo
Novo Nordisk (NYSE:NVO) said today that the FDA approved an updated label for its Saxenda liraglutide weight loss medicine. The therapy’s new label will include data showing that half of patients who received Saxenda and lost at least 5% of their weight after 56 weeks maintained their weight loss for 3 years. The update is based on data from the company’s Scale obesity and pre-diabetes 3-year trial, which evaluated the long-term safety and efficacy of Saxenda in 3,731 adults. Get the full story at our sister site, Drug Delivery Business News. The post Nordisk wins label update for weight loss drug-device c...
Source: Mass Device - April 27, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Novo Nordisk Source Type: news

ENDO: Liraglutide May Prevent Lipolysis, Ketogenesis in T1D (CME/CE)
(MedPage Today) -- Favorable results from placebo-controlled trial (Source: MedPage Today State Required CME)
Source: MedPage Today State Required CME - April 6, 2017 Category: Consumer Health News Source Type: news

Effect of Liraglutide on Liver Fat in Poorly Controlled T2D Effect of Liraglutide on Liver Fat in Poorly Controlled T2D
A new study observes the changes in liver fat content associated with liraglutide treatment in patients with uncontrolled type 2 diabetes.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 17, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Could a diabetes drug be used for Motor Neurone Disease?
(Lancaster University) A diabetes drug could one day be used to treat neurodegenerative diseases like Motor Neurone Disease (MND), Alzheimer's and Parkinson's.Researchers at Lancaster University are to conduct a clinical trial of the diabetes drug Liraglutide, giving it to patients with MND to see whether they improve or not. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 10, 2017 Category: Global & Universal Source Type: news

Once-daily liraglutide cost  effective for T2DM in the UK
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 28, 2017 Category: Drugs & Pharmacology Source Type: news

EndoBreak: Liraglutide for Prediabetes; Sugar Tax's Mixed Result; Diabetes Reversal
(MedPage Today) -- News and commentary from the endocrinology world (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - February 24, 2017 Category: Pediatrics Source Type: news

Weight loss drug could prevent type 2 diabetes
Liraglutide, a weight loss drug, reduced type 2 diabetes risk in at-risk patients by 80%, according to a study published inThe Lancet.Express (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 23, 2017 Category: Endocrinology Source Type: news

Liraglutide Associated with Less Progression in Prediabetes (FREE)
By Joe Elia Edited by William E. Chavey, MD, MS Patients with prediabetes were less likely to have developed type 2 diabetes after 3 years'treatment with liraglutide than with placebo, according to a Lancet … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 22, 2017 Category: Primary Care Source Type: news

New approach to reduce risk of developing type 2 diabetes trialled in Liverpool
(University of Liverpool) An international clinical trial conducted by the University of Liverpool has shown that the drug liraglutide 3.0 mg may reduce diabetes risk by 80 percent in individuals with obesity and prediabetes according to a study published today in The Lancet. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - February 22, 2017 Category: Global & Universal Source Type: news

Liraglutide Reduces Risk of Heart Events
(MedPage Today) -- Widely-anticipated cardiovascular outcomes trial delivers positive result (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 3, 2017 Category: Cardiology Source Type: news

Trying to Live Normally: ADA's 2017 Focus on Whole Patient Trying to Live Normally: ADA's 2017 Focus on Whole Patient
New American Diabetes Association guidelines also address early type 1 diabetes screening, defining hypoglycemia, new roles for empagliflozin and liraglutide, and vitamin B12 deficiency with metformin use.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 16, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Xultophy Injection (Insulin Degludec and Liraglutide) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 2, 2016 Category: Drugs & Pharmacology Source Type: news

Monthly News Roundup - November 2016
Novo Nordisk ’s Xultophy 100/3.6 FDA-Approved for Type 2 Diabetes This month the U.S. Food and Drug Administration (FDA) approved Novo Nordisk’s Xultophy 100/3.6 (insulin degludec and liraglutide), a once-daily injection of insulin degludec... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 30, 2016 Category: Pharmaceuticals Source Type: news

IDegLira, LixiLan Go Head-to-head as FDA OKs Both for Diabetes IDegLira, LixiLan Go Head-to-head as FDA OKs Both for Diabetes
The first approval for GLP-1 agonist lixisenatide/insulin glargine combo from Sanofi for type 2 diabetes in US will be marketed as Soliqua. Novo Nordisk product Xultophy combines liraglutide and insulin degludec.FDA Approvals (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 22, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news

Novo Nordisk Receives FDA Approval for Xultophy 100/3.6 (insulin degludec and liraglutide injection)
PLAINSBORO, N.J., Nov. 21, 2016 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for Xultophy 100/3.6 (insulin degludec 100 units/mL and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 21, 2016 Category: Drugs & Pharmacology Source Type: news

Novo Nordisk Receives FDA Approval for Xultophy 100/3.6 (insulin degludec and liraglutide injection) for Type 2 Diabetes
PLAINSBORO, N.J., Nov. 21, 2016 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application for Xultophy 100/3.6 (insulin degludec 100 units/mL and... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 21, 2016 Category: Drugs & Pharmacology Source Type: news

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news

Saxenda (Liraglutide [rDNA Origin]) Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 14, 2016 Category: Drugs & Pharmacology Source Type: news

Victoza (Liraglutide [rDNA] Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 22, 2016 Category: Drugs & Pharmacology Source Type: news

More LEADER: Liraglutide Delays Progression of Renal Events More LEADER: Liraglutide Delays Progression of Renal Events
Nephropathy results from the LEADER trial show that liraglutide reduces renal events by 22% compared with placebo, mainly driven by reduction in new-onset macroalbuminuria.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 20, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Victoza (liraglutide)
Title: Victoza (liraglutide)Category: MedicationsCreated: 2/17/2012 12:00:00 AMLast Editorial Review: 9/14/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - September 14, 2016 Category: Endocrinology Source Type: news

Switching GLP-1 For DPP-4 Improves Net T2D Outcomes
(MedPage Today) -- Victoza bests Januvia for combo therapy on A1c, weight, hypoglycemia composite (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 13, 2016 Category: Cardiology Source Type: news

Novo's Insulin/GLP-1 Agonist Combo IDegLira Delayed in US Novo's Insulin/GLP-1 Agonist Combo IDegLira Delayed in US
IDegLira, the Novo Nordisk injectable combination of insulin degludec and liraglutide, has received a setback in the United States where the FDA says it needs 3 more months to consider approval.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 6, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Weight Loss Pills And Products Don't Work And Aren't Safe
Our ancestors lived in a feast or famine world. When you don't know where your next meal is coming from, or when it will arrive, the smart play is to pig out every time food is available. Our genes are programmed to extract as much energy as possible from what we eat and to store any extra energy in fat reservoirs, available in reserve for future famines. These deeply ingrained genetic tendencies worked great in the austere world of our ancestors, but are a disaster in our current world of refrigerators, ubiquitous fast food joints and milk shakes. Only one third of Americans are now able to maintain a normal weight; one ...
Source: Science - The Huffington Post - September 5, 2016 Category: Science Source Type: news

FDA Extends Regulatory Review Period for IDegLira by Three Months
Bagsv ærd, Denmark, 2 September 2016 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has extended the regulatory review period for IDegLira, the fixed-ratio combination of insulin degludec and liraglutide in adults with... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - September 2, 2016 Category: Drugs & Pharmacology Source Type: news

The Effects of Liraglutide on Insulin Allergy in T2DM The Effects of Liraglutide on Insulin Allergy in T2DM
This case suggests that the GLP-1 analog liraglutide might be a useful alternative for treatment of insulin allergy and anti-insulin antibodies in patients with type 2 diabetes.Journal of Medical Case Reports (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 25, 2016 Category: Allergy & Immunology Tags: Diabetes & Endocrinology Journal Article Source Type: news

Mixed Results for Liraglutide in Type 1 Diabetes: ADJUNCT 1, 2 Mixed Results for Liraglutide in Type 1 Diabetes: ADJUNCT 1, 2
Two studies show glucose and weight benefits but also adverse events with liraglutide added to insulin in type 1 diabetes.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 17, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Diabetes Drugs: The Latest Good -- and Bad -- News Diabetes Drugs: The Latest Good -- and Bad -- News
Dr Anne Peters discusses hot topics in type 2 diabetes treatment: liraglutide shows CV benefits, whereas some SGLT2 inhibitors show renal protection -- and potential harm.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 16, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news

Triple Therapy in Type 1 Diabetes Improves Glycemic Control but Carries Ketosis Risks (FREE)
By Amy Orciari Herman Edited by Andr é Sofair, MD, MPH, and William E. Chavey, MD, MS Adding dapagliflozin to liraglutide and insulin in patients with type 1 diabetes lowers hemoglobin A1c levels but poses risk for ketoacidosis, … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 4, 2016 Category: Primary Care Source Type: news

Liraglutide No Help in Advanced HF Patients (CME/CE)
(MedPage Today) -- Trend toward worse outcomes reported in diabetes subgroup (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 4, 2016 Category: Cardiology Source Type: news